Wnt/β-catenin activation by mutually exclusive FBXW11 and CTNNB1 hotspot mutations drives salivary basal cell adenoma.
AuteursWong K, Bishop JA, Weinreb I, Motta M, Del Castillo Velasco-Herrera M, Bellacchio E, Ferreira I, van der Weyden L, Boccacino JM, Lauri A, Rotundo G, Ciolfi A, Cheema S, Olvera-León R, Offord V, Droop A, Vermes I, Allgäuer M, Hyrcza M, Anderson E, Smith K, de Saint Aubain N, Mogler C, Stenzinger A, Arends MJ, Brenn T, Tartaglia M, Adams DJ
Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial.
AuteursDauccia C, Alice Franzoi M, Martel S, Agbor-Tarh D, Fielding S, Piccart M, Bines J, Loibl S, Di Cosimo S, Vaz-Luis I, Di Meglio A, Del Mastro L, Gombos A, Desmedt C, Jerusalem G, Reaby L, Pienkowski T, Lambertini M, Agostinetto E, Azambuja E
Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial.
AuteursDauccia C, Alice Franzoi M, Martel S, Agbor-Tarh D, Fielding S, Piccart M, Bines J, Loibl S, Di Cosimo S, Vaz-Luis I, Di Meglio A, Del Mastro L, Gombos A, Desmedt C, Jerusalem G, Reaby L, Pienkowski T, Lambertini M, Agostinetto E, Azambuja E
Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial.
AuteursDauccia C, Alice Franzoi M, Martel S, Agbor-Tarh D, Fielding S, Piccart M, Bines J, Loibl S, Di Cosimo S, Vaz-Luis I, Di Meglio A, Del Mastro L, Gombos A, Desmedt C, Jerusalem G, Reaby L, Pienkowski T, Lambertini M, Agostinetto E, Azambuja E
Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial.
AuteursDauccia C, Alice Franzoi M, Martel S, Agbor-Tarh D, Fielding S, Piccart M, Bines J, Loibl S, Di Cosimo S, Vaz-Luis I, Di Meglio A, Del Mastro L, Gombos A, Desmedt C, Jerusalem G, Reaby L, Pienkowski T, Lambertini M, Agostinetto E, Azambuja E
Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR.
AuteursÖcal O, Zech CJ, Bali MA, Pasquier D, Mottaghy F, Einspieler I, Kartalis N, Bargellini I, Iezzi R, Denecke T, Kunz WG, Gebauer B, Wege H, Cannella R, Oprea-Lager DE, Vogel A, Sangro B, Seidensticker M
Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trial.
AuteursCollet L, Ardin M, Venet D, Berthet J, Ghamry-Barrin S, Treilleux I, Noel JC, Leheurteur M, Meunier J, Bengrine Lefevre L, Martinez M, Priou F, Selle F, Just PA, Bataillon G, Rothé F, Sotiriou C, Caux C, Dubois B, Ray-Coquard I, Le Saux O
